Galvin Gaustad & Stein LLC Invests $8.96 Million in United Therapeutics Co. (NASDAQ:UTHR)

Galvin Gaustad & Stein LLC purchased a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,007 shares of the biotechnology company's stock, valued at approximately $8,961,000. Galvin Gaustad & Stein LLC owned 0.06% of United Therapeutics at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 42 shares during the period. V Square Quantitative Management LLC purchased a new position in United Therapeutics in the 2nd quarter worth about $30,000. Innealta Capital LLC bought a new stake in United Therapeutics during the 2nd quarter valued at about $33,000. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Capital Performance Advisors LLP bought a new position in United Therapeutics in the 3rd quarter worth about $82,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. LADENBURG THALM/SH SH lifted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Bank of America lowered their target price on United Therapeutics from $303.00 to $280.00 and set an "underperform" rating for the company in a report on Thursday, August 1st. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. TD Cowen upped their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, October 21st. Finally, The Goldman Sachs Group increased their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $370.86.

United Therapeutics Stock Performance

NASDAQ:UTHR traded up $7.43 during midday trading on Friday, reaching $410.00. 498,743 shares of the stock traded hands, compared to its average volume of 464,869. The stock has a market capitalization of $18.30 billion, a PE ratio of 18.01, a price-to-earnings-growth ratio of 1.16 and a beta of 0.56. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The business has a 50-day moving average of $359.20 and a two-hundred day moving average of $322.77.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the business posted $5.38 EPS. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Co. will post 25.1 earnings per share for the current year.

Insider Activity

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the business's stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares of the company's stock, valued at approximately $1,384,115.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO James Edgemond sold 7,785 shares of United Therapeutics stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the completion of the sale, the chief financial officer now owns 2,615 shares of the company's stock, valued at $947,597.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the transaction, the director now owns 3,675 shares in the company, valued at approximately $1,384,115.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 96,422 shares of company stock worth $35,251,428 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.